Status:
RECRUITING
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
Lead Sponsor:
University of California, San Francisco
Collaborating Sponsors:
National Institutes of Health (NIH)
Conditions:
HIV
Eligibility:
All Genders
18-70 years
Brief Summary
HIV medicines have led to dramatic improvements in health. However, there remains a concern for potential drug toxicities, cost of drugs, and need for life-long treatment. In addition, research has fo...
Eligibility Criteria
Inclusion
- Able to give informed consent
- No contraindication to surgical procedures
- Palpable inguinal adenopathy at study entry
- For HIV seropositive subjects, meeting one of the following criteria: (1) on stable highly active antiretroviral therapy (HAART) with a recent undetectable viral load (\< 50 copies/mL) ("HAART suppressed"), (2) antiretroviral untreated with an undetectable viral load (\< 50 copies/mL) ("elite" controllers), or (3) antiretroviral untreated with a detectable viral load (\> 1000 copies/mL) ("non-controllers")
Exclusion
- Known anemia (HIV+ males Hct\<34; females Hct\<32) or contraindication to donating blood
- Blood coagulation disorder (including bleeding tendency or problems in past with blood clots)
- Platelets \< 50,000/mm3
- PTT \> 2x ULN
- INR \> 1.5
- Pregnant
Key Trial Info
Start Date :
April 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2030
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT01202305
Start Date
April 1 2011
End Date
April 1 2030
Last Update
April 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
San Francisco General Hospital
San Francisco, California, United States, 94110